P49682 (CXCR3_HUMAN) Reviewed, UniProtKB/Swiss-Prot

Names and origin

Protein names

Recommended name:
C-X-C chemokine receptor type 3
Short name=CXC-R3
Short name=CXCR-3

Alternative name(s):
CKR-L2
G protein-coupled receptor 9
Interferon-inducible protein 10 receptor
Short name=IP-10 receptor
CD_antigen=CD183

Gene names

Name:	CXCR3
Synonyms:	GPR9

Organism

Homo sapiens (Human) [Reference proteome]

Taxonomic identifier

9606 [NCBI]

Taxonomic lineage

cellular organisms › Eukaryota › Opisthokonta › Metazoa › Eumetazoa › Bilateria › Deuterostomia › Chordata › Craniata › Vertebrata › Gnathostomata › Teleostomi › Euteleostomi › Sarcopterygii › Tetrapoda › Amniota › Mammalia › Theria › Eutheria › Euarchontoglires › Primates › Haplorrhini › Simiiformes › Catarrhini › Hominoidea › Hominidae › Homininae › Homo

Protein attributes

Sequence length	368 AA.
Sequence status	Complete.
Protein existence	Evidence at protein level

General annotation (Comments)

Function	Receptor for CXCL9, CXCL10 and CXCL11 and mediates the proliferation of human mesangial cells (HMC). Ref.2 Ref.3 Ref.10 Ref.14 Isoform 2 is a receptor for CXCL4 and also mediates the inhibitory activities of CXCL9, CXCL10 and CXCL11 on the growth of human microvascular endothelial cells (HMVEC). Interaction with CXCL4 or CXCL10 leads to activation of the p38MAPK pathway and contributes to inhibition of angiogenesis. Overexpression in renal cancer cells down-regulates expression of the anti-apoptotic protein HMOX1 and promotes apoptosis. Ref.2 Ref.3 Ref.10 Ref.14 Isoform 3 mediates the activity of CXCL11. Ref.2 Ref.3 Ref.10 Ref.14
Subcellular location	Cell membrane; Multi-pass membrane protein.
Tissue specificity	Isoform 1 and isoform 2 are mainly expressed in heart, kidney, liver and skeletal muscle. Isoform 1 is also expressed in placenta. Ref.2
Post-translational modification	Sulfation on Tyr-27 and Tyr-29 is essential for CXCL10 binding and subsequent signal transduction induction. N-glycosylated.
Sequence similarities	Belongs to the G-protein coupled receptor 1 family.
Sequence caution	The sequence CAB02143.1 differs from that shown. Reason: Erroneous initiation.

Ontologies

Keywords
Biological process	Angiogenesis Apoptosis
Cellular component	Cell membrane Membrane
Coding sequence diversity	Alternative splicing Polymorphism
Domain	Transmembrane Transmembrane helix
Molecular function	G-protein coupled receptor Receptor Transducer
PTM	Disulfide bond Glycoprotein Sulfation
Technical term	Complete proteome Reference proteome
Gene Ontology (GO)
Biological_process	T cell chemotaxis Inferred from electronic annotation. Source: Compara angiogenesis Inferred from electronic annotation. Source: UniProtKB-KW apoptotic process Inferred from electronic annotation. Source: UniProtKB-KW calcium-mediated signaling Inferred from electronic annotation. Source: Compara cell adhesion Traceable author statement PubMed 10942362. Source: ProtInc cellular component movement Traceable author statement PubMed 10741397. Source: ProtInc chemotaxis Traceable author statement PubMed 10903763. Source: ProtInc elevation of cytosolic calcium ion concentration Traceable author statement PubMed 10903743. Source: ProtInc
Cellular_component	cytoplasm Traceable author statement PubMed 10903743. Source: ProtInc external side of plasma membrane Inferred from electronic annotation. Source: Compara integral to plasma membrane Traceable author statement Ref.1. Source: ProtInc
Molecular_function	C-X-C chemokine receptor activity Inferred from electronic annotation. Source: Compara chemokine receptor activity Traceable author statement Ref.1. Source: ProtInc
Complete GO annotation...

Alternative products

This entry describes 3 isoforms produced by alternative splicing. [Align] [Select]

Isoform 1 (identifier: P49682-1)

Also known as: CXCR3-A;

This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.

Isoform 2 (identifier: P49682-2)

Also known as: CXCR3-B;

The sequence of this isoform differs from the canonical sequence as follows:
     1-4: MVLE → MELRKYGPGRLAGTVIGGAAQSKSQTKSDSITKEFLPGLYTAPSSPFPPSQ

Isoform 3 (identifier: P49682-3)

Also known as: CXCR3-alt;

The sequence of this isoform differs from the canonical sequence as follows:
     210-368: VGRTALRVLQ...ETSEASYSGL → GSSSGSGCGC...AGIRAPLSPI

Note: Due to exon skipping.

Sequence annotation (Features)

	Feature key	Position(s)	Length	Description	Graphical view	Feature identifier
Molecule processing
	Chain	1 – 368	368	C-X-C chemokine receptor type 3		PRO_0000069346
Regions
	Topological domain	1 – 53	53	Extracellular Potential
	Transmembrane	54 – 80	27	Helical; Name=1; Potential
	Topological domain	81 – 89	9	Cytoplasmic Potential
	Transmembrane	90 – 110	21	Helical; Name=2; Potential
	Topological domain	111 – 125	15	Extracellular Potential
	Transmembrane	126 – 147	22	Helical; Name=3; Potential
	Topological domain	148 – 169	22	Cytoplasmic Potential
	Transmembrane	170 – 189	20	Helical; Name=4; Potential
	Topological domain	190 – 212	23	Extracellular Potential
	Transmembrane	213 – 233	21	Helical; Name=5; Potential
	Topological domain	234 – 255	22	Cytoplasmic Potential
	Transmembrane	256 – 277	22	Helical; Name=6; Potential
	Topological domain	278 – 298	21	Extracellular Potential
	Transmembrane	299 – 321	23	Helical; Name=7; Potential
	Topological domain	322 – 368	47	Cytoplasmic Potential
Amino acid modifications
	Modified residue	27	1	Sulfotyrosine Ref.12 Ref.13
	Modified residue	29	1	Sulfotyrosine Ref.13
	Glycosylation	22	1	N-linked (GlcNAc...) Potential
	Glycosylation	32	1	N-linked (GlcNAc...) Potential
	Disulfide bond	124 ↔ 203		By similarity
Natural variations
	Alternative sequence	1 – 4	4	MVLE → MELRKYGPGRLAGTVIGGAA QSKSQTKSDSITKEFLPGLY TAPSSPFPPSQ in isoform 2.		VSP_015684
	Alternative sequence	210 – 368	159	VGRTA…SYSGL → GSSSGSGCGCCSCAWAAPTR EGSRGSHRLPAGIHPGLRPQ RPPTRACEAGIRAPLSPI in isoform 3.		VSP_015685
	Natural variant	292	1	R → Q. Ref.9		VAR_016240
	Natural variant	363	1	A → T. Ref.9		VAR_016241
Experimental info
	Mutagenesis	1 – 16	16	Missing: Reduces binding to CXCL10 and CXCL11, and reduces CXCL10- and CXCL11-induced chemotaxis and activation. Does not affect CXCL9-induced chemotaxis and activation. Ref.12
	Mutagenesis	4	1	E → K: Does not affect binding to CXCL9, CXCL10 and CXCL11 or activation. Ref.12
	Mutagenesis	21	1	E → K: Reduces slightly CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Ref.12
	Mutagenesis	27 – 29	3	YDY → ADA: Abolishes binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Ref.12 Ref.13
	Mutagenesis	27	1	Y → F: Reduces sulfation and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Abolishes binding to CXCL10. Abolishes sulfation, binding to CXCL11, ligand-induced receptor internalization and CXCL9-, CXCL10- and CXCL11-induced chemotaxis; when associated with F-29. Ref.12 Ref.13
	Mutagenesis	29	1	Y → F: Reduces sulfation, binding to CXCL10 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Abolishes sulfation, binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis; when associated with F-27. Ref.12 Ref.13
	Mutagenesis	112	1	D → A: Abolishes binding to CXCL10 and CXCL11. Reduces CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Ref.12
	Mutagenesis	112	1	D → K: Abolishes binding to CXCL10 and CXCL11 and CXCL10- and CXCL11-induced chemotaxis. Reduces CXCL9-induced chemotaxis. Ref.12
	Mutagenesis	197	1	R → A: Abolishes binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Reduces ligand-induced receptor internalization. Ref.12
	Mutagenesis	212	1	R → A: Abolishes CXCL10-induced chemotaxis. Reduces CXCL9- and CXCL11-induced chemotaxis. Does not affect binding to CXCL10 and CXCL11. Ref.12
	Mutagenesis	216	1	R → A: Reduces CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Does not affect binding to CXCL10 and CXCL11 or receptor internalization. Ref.12
	Mutagenesis	278	1	D → A: Abolishes binding to CXCL10 and CXCL11 and CXCL11-induced chemotaxis. Reduces CXCL9 and CXCL10-induced chemotaxis. Ref.12
	Mutagenesis	278	1	D → K: Abolishes binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Ref.12
	Mutagenesis	282	1	D → A: Reduces binding to CXCL10 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Abolishes binding to CXCL11. Ref.12
	Mutagenesis	282	1	D → K: Reduces binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Ref.12
	Mutagenesis	293	1	E → A: Reduces binding to CXCL10 and CXCL9- and CXCL11-induced chemotaxis. Abolishes binding to CXCL11 and CXCL10-induced chemotaxis. Ref.12
	Mutagenesis	293	1	E → K: Abolishes binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Ref.12
	Sequence conflict	75	1	A → R in CAB02143. Ref.4
	Sequence conflict	157	1	T → I in BAG36429. Ref.6

Sequences

	Sequence		Length	Mass (Da)
	Isoform 1 (CXCR3-A) [UniParc]. Last modified November 1, 1997. Version 2. Checksum: F08A3B44B2BBAD04	FASTA	368	40,660
	10 20 30 40 50 60 MVLEVSDHQV LNDAEVAALL ENFSSSYDYG ENESDSCCTS PPCPQDFSLN FDRAFLPALY 70 80 90 100 110 120 SLLFLLGLLG NGAVAAVLLS RRTALSSTDT FLLHLAVADT LLVLTLPLWA VDAAVQWVFG 130 140 150 160 170 180 SGLCKVAGAL FNINFYAGAL LLACISFDRY LNIVHATQLY RRGPPARVTL TCLAVWGLCL 190 200 210 220 230 240 LFALPDFIFL SAHHDERLNA THCQYNFPQV GRTALRVLQL VAGFLLPLLV MAYCYAHILA 250 260 270 280 290 300 VLLVSRGQRR LRAMRLVVVV VVAFALCWTP YHLVVLVDIL MDLGALARNC GRESRVDVAK 310 320 330 340 350 360 SVTSGLGYMH CCLNPLLYAF VGVKFRERMW MLLLRLGCPN QRGLQRQPSS SRRDSSWSET SEASYSGL
	Isoform 2 (CXCR3-B) [UniParc]. Checksum: 325C8A65982A43C4	FASTA	415	45,523
	10 20 30 40 50 60 MELRKYGPGR LAGTVIGGAA QSKSQTKSDS ITKEFLPGLY TAPSSPFPPS QVSDHQVLND 70 80 90 100 110 120 AEVAALLENF SSSYDYGENE SDSCCTSPPC PQDFSLNFDR AFLPALYSLL FLLGLLGNGA 130 140 150 160 170 180 VAAVLLSRRT ALSSTDTFLL HLAVADTLLV LTLPLWAVDA AVQWVFGSGL CKVAGALFNI 190 200 210 220 230 240 NFYAGALLLA CISFDRYLNI VHATQLYRRG PPARVTLTCL AVWGLCLLFA LPDFIFLSAH 250 260 270 280 290 300 HDERLNATHC QYNFPQVGRT ALRVLQLVAG FLLPLLVMAY CYAHILAVLL VSRGQRRLRA 310 320 330 340 350 360 MRLVVVVVVA FALCWTPYHL VVLVDILMDL GALARNCGRE SRVDVAKSVT SGLGYMHCCL 370 380 390 400 410 NPLLYAFVGV KFRERMWMLL LRLGCPNQRG LQRQPSSSRR DSSWSETSEA SYSGL
	Isoform 3 (CXCR3-alt) [UniParc]. Checksum: 8E5C6052A5A3E518	FASTA	267	28,715
	10 20 30 40 50 60 MVLEVSDHQV LNDAEVAALL ENFSSSYDYG ENESDSCCTS PPCPQDFSLN FDRAFLPALY 70 80 90 100 110 120 SLLFLLGLLG NGAVAAVLLS RRTALSSTDT FLLHLAVADT LLVLTLPLWA VDAAVQWVFG 130 140 150 160 170 180 SGLCKVAGAL FNINFYAGAL LLACISFDRY LNIVHATQLY RRGPPARVTL TCLAVWGLCL 190 200 210 220 230 240 LFALPDFIFL SAHHDERLNA THCQYNFPQG SSSGSGCGCC SCAWAAPTRE GSRGSHRLPA 250 260 GIHPGLRPQR PPTRACEAGI RAPLSPI

References

	« Hide 'large scale' referencesShow 'large scale' references »
[1]	"Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes." Loetscher M., Gerber B., Loetscher P., Jones S.A., Piali L., Clark-Lewis I., Baggiolini M., Moser B. J. Exp. Med. 184:963-969(1996) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). Tissue: Blood.
[2]	"An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4." Lasagni L., Francalanci M., Annunziato F., Lazzeri E., Giannini S., Cosmi L., Sagrinati C., Mazzinghi B., Orlando C., Maggi E., Marra F., Romagnani S., Serio M., Romagnani P. J. Exp. Med. 197:1537-1549(2003) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, TISSUE SPECIFICITY.
[3]	"Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B." Petrai I., Rombouts K., Lasagni L., Annunziato F., Cosmi L., Romanelli R.G., Sagrinati C., Mazzinghi B., Pinzani M., Romagnani S., Romagnani P., Marra F. Int. J. Biochem. Cell Biol. 40:1764-1774(2008) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION. Tissue: Endothelial cell and Thymus.
[4]	Gutierrez J., Varona R., Zaballos A., Lind P., Marquez G. Submitted (SEP-1996) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
[5]	"cDNA clones of human proteins involved in signal transduction sequenced by the Guthrie cDNA resource center (www.cdna.org)." Warren C.N., Aronstam R.S., Sharma S.V. Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). Tissue: Leukocyte.
[6]	"Complete sequencing and characterization of 21,243 full-length human cDNAs." Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S. , Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S. Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). Tissue: Colon.
[7]	"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). Tissue: Brain, Lung and Testis.
[8]	"Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors." Marchese A., Heiber M., Nguyen T., Heng H.H.Q., Saldivia V.R., Cheng R., Murphy P.M., Tsui L.-C., Shi X., Gregor P., George S.R., O'Dowd B.F., Docherty J.M. Genomics 29:335-344(1995) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 5-368.
[9]	"Single nucleotide polymorphisms in the coding regions of human CXC-chemokine receptors CXCR1, CXCR2 and CXCR3." Kato H., Tsuchiya N., Tokunaga K. Genes Immun. 1:330-337(2000) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 278-368, VARIANTS GLN-292 AND THR-363.
[10]	"Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping." Ehlert J.E., Addison C.A., Burdick M.D., Kunkel S.L., Strieter R.M. J. Immunol. 173:6234-6240(2004) [PubMed] [Europe PMC] [Abstract] Cited for: ALTERNATIVE SPLICING (ISOFORM 3), FUNCTION.
[11]	"Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3." Cole K.E., Strick C.A., Paradis T.J., Ogborne K.T., Loetscher M., Gladue R.P., Lin W., Boyd J.G., Moser B., Wood D.E., Sahagan B.G., Neote K. J. Exp. Med. 187:2009-2021(1998) [PubMed] [Europe PMC] [Abstract] Cited for: LIGAND-BINDING. Tissue: Fetal astrocyte.
[12]	"CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis." Colvin R.A., Campanella G.S., Manice L.A., Luster A.D. Mol. Cell. Biol. 26:5838-5849(2006) [PubMed] [Europe PMC] [Abstract] Cited for: SULFATION AT TYR-27, MUTAGENESIS OF 1-MET--VAL-16; GLU-4; GLU-21; TYR-27; 27-TYR--TYR-29; TYR-29; ASP-112; ARG-197; ARG-212; ARG-216; ASP-278; ASP-282 AND GLU-293.
[13]	"Sulfated tyrosines 27 and 29 in the N-terminus of human CXCR3 participate in binding native IP-10." Gao J.M., Xiang R.L., Jiang L., Li W.H., Feng Q.P., Guo Z.J., Sun Q., Zeng Z.P., Fang F.D. Acta Pharmacol. Sin. 30:193-201(2009) [PubMed] [Europe PMC] [Abstract] Cited for: SULFATION AT TYR-27 AND TYR-29, MUTAGENESIS OF TYR-27 AND TYR-29.
[14]	"CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1." Datta D., Banerjee P., Gasser M., Waaga-Gasser A.M., Pal S. J. Biol. Chem. 285:36842-36848(2010) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION.
+	Additional computationally mapped references.

Web resources

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Wikipedia

CXC chemokine receptors entry

Cross-references

Sequence databases
EMBL GenBank DDBJ	X95876 mRNA. Translation: CAA65126.1. AF469635 mRNA. Translation: AAP55851.1. Z79783 Genomic DNA. Translation: CAB02143.1. Different initiation. AY242128 mRNA. Translation: AAO92295.1. AK313679 mRNA. Translation: BAG36429.1. BC034403 mRNA. Translation: AAH34403.1. U32674 Genomic DNA. Translation: AAC50505.1. AB032735 Genomic DNA. Translation: BAA92297.1. AB032736 Genomic DNA. Translation: BAA92298.1.
IPI	IPI00027754. IPI00640020. IPI00651732.
RefSeq	NP_001136269.1. NM_001142797.1. NP_001495.1. NM_001504.1.
UniGene	Hs.198252.
3D structure databases
ProteinModelPortal	P49682.
ModBase	Search...
Protein-protein interaction databases
DIP	DIP-5891N.
STRING	9606.ENSP00000362795.
Protein family/group databases
GPCRDB	Search...
PTM databases
PhosphoSite	P49682.
Polymorphism databases
DMDM	2829400.
Proteomic databases
PaxDb	P49682.
PRIDE	P49682.
Protocols and materials databases
DNASU	2833.
StructuralBiologyKnowledgebase	Search...
Genome annotation databases
Ensembl	ENST00000373691; ENSP00000362795; ENSG00000186810. ENST00000373693; ENSP00000362797; ENSG00000186810.
GeneID	2833.
KEGG	hsa:2833.
UCSC	uc004eaf.3. human. uc011mpx.2. human.
Organism-specific databases
CTD	2833.
GeneCards	GC0XM070835.
HGNC	HGNC:4540. CXCR3.
HPA	CAB017820.
MIM	300574. gene.
neXtProt	NX_P49682.
PharmGKB	PA35049.
GenAtlas	Search...
Phylogenomic databases
eggNOG	NOG150428.
HOGENOM	HOG000234122.
HOVERGEN	HBG106917.
KO	K04188.
OMA	AYCYARI.
PhylomeDB	P49682.
Enzyme and pathway databases
Reactome	REACT_111102. Signal Transduction.
Gene expression databases
Bgee	P49682.
CleanEx	HS_CXCR3.
Genevestigator	P49682.
GermOnline	ENSG00000186810. Homo sapiens.
Family and domain databases
InterPro	IPR004070. Chemokine_CXCR3. IPR000355. Chemokine_rcpt. IPR000276. GPCR_Rhodpsn. IPR017452. GPCR_Rhodpsn_7TM. [Graphical view]
Pfam	PF00001. 7tm_1. 1 hit. [Graphical view]
PRINTS	PR00657. CCCHEMOKINER. PR01532. CXCCHMKINER3. PR00237. GPCRRHODOPSN.
PROSITE	PS00237. G_PROTEIN_RECEP_F1_1. 1 hit. PS50262. G_PROTEIN_RECEP_F1_2. 1 hit. [Graphical view]
ProtoNet	Search...
Other
BindingDB	P49682.
ChEMBL	CHEMBL4441.
GenomeRNAi	2833.
NextBio	11181.
SOURCE	Search...

Entry information

Entry name

CXCR3_HUMAN

Accession

Primary (citable) accession number: P49682
Secondary accession number(s): B2R982 , O15185, Q7Z710, Q9P2T4, Q9P2T5

Entry history

Integrated into UniProtKB/Swiss-Prot:	February 1, 1996
Last sequence update:	November 1, 1997
Last modified:	May 1, 2013
This is version 134 of the entry and version 2 of the sequence. [Complete history]

Entry status

Reviewed (UniProtKB/Swiss-Prot)

Annotation program

Chordata Protein Annotation Program

Disclaimer

Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.